The international surgical journal with global reach

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824-1835.

Published: 25th January 2018

Authors: Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al.

Conclusion

In this trial that included 906 patients, the active agents were given intravenously for up to one year. Twelve month recurrence-free survival was 70.5 per cent with nivolumab and 60.8 per cent with ipilimumab, P<0.001. Side effects were more common with ipilimumab (45.9 versus 14.4 per cent).

Pubmed Link

You may also be interested in

Scientific Surgery

Five-year analysis of adjuvant dabrafenib plus trametinib in Stage III Melanoma. N Engl J Med 2020; 383: 1139-1148.

Authors: Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM et al.

Scientific Surgery

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 395: 1558-1568.

Authors: Zimmer S, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C et al.

Scientific Surgery

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019; 394: 471-477.

Authors: Utjes D, Malmstedt J, Teras J, Drzewiecki K, Gullestad HP, Ingvar C et al.

Scientific Surgery

Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789-1801.

Authors: Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al.

Scientific Surgery

Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377: 1813-1823.

Authors: Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al.

Scientific Surgery

Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376: 2211-2222.

Authors: Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al.

Scientific Surgery

Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376: 2211-2222.

Authors: Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al.

Scientific Surgery

Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol 2017; 35: 885-892.

Authors: Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI et al.

Scientific Surgery

Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845-1855.

Authors: Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al.

Scientific Surgery

Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 2016; 34: 1079-1086.

Authors: McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD et al.